Literature DB >> 2989339

Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels.

L M Pilarski, B A Ruether, M J Mant.   

Abstract

Multiple myeloma patients are deficient in normal polyclonal serum immunoglobulins. To determine the reasons for this decrease, we quantitated and compared the number of surface IgM+ B lymphocytes, and the number of B cells susceptible to transformation by Epstein-Barr virus (EBV) with the concentration of IgM in serum. Serum IgM levels varied considerably in individual patients, temporally shifting from undetectable to normal amounts and then dropping again to undetectable levels. A transient rise to normal serum IgM concentrations was seen in 42% of patients assessed at two or more time points. Of 44 patients, 52% showed a lack of correlation between the number of surface IgM+ (sIgM+) B cells and serum IgM concentration. One subset of patients (25%) had detectable to normal numbers of sIgM+ B cells in blood but undetectable levels of serum IgM. Transformation of B cells from these patients indicated a block in IgM secretion that was extrinsic to the B cells that were fully able to transcribe, translate, and secrete IgM after EBV transformation. A second subset of patients (27%) had undetectable numbers of sIgM+ B cells but near normal levels of serum IgM, suggesting abundant secretion by few clones of B cells. Of 18 patients with monoclonal gammopathy of undetermined significance (MGUS), 26% showed a lack of correlation between the numbers of sIgM+ B cells and serum IgM concentration. We suggest that in patients with multiple myeloma, and in some with MGUS, there exists a mechanism(s) extrinsic to the B cell that mediates an arrest in terminal B lymphocyte maturation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989339      PMCID: PMC425563          DOI: 10.1172/JCI111921

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes.

Authors:  F D Lindström; W R Hardy; B J Eberle; R C Williams
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

2.  Primary immunodeficiency with increased numbers of circulating B lymphocytes contrasting with hypogammaglobulinaemia.

Authors:  J L Preud'homme; M Seligmann
Journal:  Lancet       Date:  1972-02-19       Impact factor: 79.321

3.  Agammaglobulinaemia with B lymphocytes. Specific defect of plasma-cell differentiation.

Authors:  M D Cooper; A R Lawton; D E Bockman
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

4.  Development of a second monoclonal immunoglobulin G in a patient with late manifestation of myeloma.

Authors:  G A Spengler; A G Steinberg; F Skvaril
Journal:  Acta Med Scand       Date:  1972-10

5.  Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients.

Authors:  L M Pilarski; M J Mant; B A Ruether; A Belch
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.

Authors:  L Winger; C Winger; P Shastry; A Russell; M Longenecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets.

Authors:  D Peest; U Brunkhorst; I Schedel; H Deicher
Journal:  Scand J Immunol       Date:  1984-02       Impact factor: 3.487

8.  B and T lymphocytes in primary immunodeficiency disease in man.

Authors:  K J Gajl-Peczalska; B H Park; W D Biggar; R A Good
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

9.  Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia.

Authors:  H M Grey; E Rabellino; B Pirofsky
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

10.  Human-human B cell hybridomas from in vitro stimulated lymphocytes of patients with common variable immunodeficiency.

Authors:  K A Denis; R Wall; A Saxon
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

View more
  9 in total

1.  Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease.

Authors:  S Pollack; R Katz; I Tatarsky; A Carter
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

Review 3.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

4.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

5.  Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma.

Authors:  X G Zhang; B Klein; C Duperray; J Brochier; R Bataille
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Specificity repertoire of lymphocytes from multiple myeloma patients. I. High frequency of B cells specific for idiotypic and F(ab')2-region determinants on immunoglobulin.

Authors:  L M Pilarski; M Piotrowska-Krezolak; D J Gibney; L Winger; C Winger; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

7.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

Authors:  Linda M Pilarski; Eva Baigorri; Michael J Mant; Patrick M Pilarski; Penelope Adamson; Heddy Zola; Andrew R Belch
Journal:  Clin Med Oncol       Date:  2008-03-27

9.  Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Authors:  Sebastian Kobold; Tim Luetkens; Britta Marlen Bartels; Yanran Cao; York Hildebrandt; Orhan Sezer; Henrike Reinhard; Julia Templin; Katrin Bartels; Nesrine Lajmi; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic
Journal:  Clin Dev Immunol       Date:  2012-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.